Amplia Therapeutics Limited (ASX: ATX) is entering a compelling phase in its clinical journey, as recent announcements reinforce the growing potential of its lead compound, narmafotinib (AMP945), in the fight against advanced pancreatic cancer(Figure 1). With news of two rare and confirmed complete responses emerging from the ongoing ACCENT trial, investors have reason to take notice. These outcomes are not only clinically remarkable—they may signal a turning point in one of